Bulletin
Investor Alert

New York Markets Open in:

Market Pulse Archives

Aug. 15, 2022, 8:15 a.m. EDT

Novavax submits FDA application for its COVID-19 booster

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Novavax Inc. (NVAX)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Novavax Inc. /zigman2/quotes/202614340/composite NVAX -3.61% said Monday that it asked the Food and Drug Administration to authorize its COVID-19 booster for adults. The company's primary series of protein-based shots received FDA authorization in July. "We believe our vaccine offers a broad, long-lasting immune response against a range of variants," Novavax CEO Stanley Erck said in a news release. Novavax said giving a third shot of its vaccine to adults six months after getting the first two Novavax shots boosted antibody levels that were comparable to or exceeded levels reported after the first two shots. Novavax's stock has declined 71.0% this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX -0.20% is down 10.2%.

/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 18.70
-0.70 -3.61%
Volume: 3.66M
Oct. 5, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.52 billion
Rev. per Employee
$837,729
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,783.28
-7.65 -0.20%
Volume: 2.22B
Oct. 5, 2022 5:03p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.